OMNIAB, INC. Operating Expenses
OMNIAB, INC. (OABI) reported Operating Expenses of $20.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-06
- OMNIAB, INC. operating expenses for the quarter ending 2026-06-30 was $20.05M, a 0.32% decline year-over-year.
- OMNIAB, INC. operating expenses for the quarter ending 2026-03-31 was $22.26M, a 3.23% decline year-over-year.
- OMNIAB, INC. operating expenses for the quarter ending 2025-12-31 was $24.14M, a 9.53% decline year-over-year.
- OMNIAB, INC. operating expenses for the quarter ending 2025-09-30 was $20.38M, a 14.86% decline year-over-year.
- OMNIAB, INC. operating expenses for fiscal 2025 was $87.64M, a 13.14% decline from fiscal 2024.
- OMNIAB, INC. operating expenses for fiscal 2024 was $100.89M, a 2.60% decline from fiscal 2023.
- OMNIAB, INC. operating expenses for fiscal 2023 was $103.58M, a 20.83% increase from fiscal 2022.
- OMNIAB, INC. operating expenses for fiscal 2022 was $85.72M, a 21.84% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $20.05M 10-Q · filed 2026-08-06 | $42.31M 10-Q · filed 2026-08-06 | $66.45M derived: sum of 3 quarters · filed 2026-08-06 | $86.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $22.26M 10-Q · filed 2026-05-07 | $46.40M derived: sum of 2 quarters · filed 2026-05-07 | $66.78M derived: sum of 3 quarters · filed 2026-05-07 | $86.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.14M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $44.52M derived: sum of 2 quarters · filed 2026-03-04 | $64.64M derived: sum of 3 quarters · filed 2026-08-06 | $87.64M 10-K · filed 2026-03-04 |
| 2025-09-30 | $20.38M 10-Q · filed 2025-11-04 | $40.49M derived: sum of 2 quarters · filed 2026-08-06 | $63.49M 10-Q · filed 2025-11-04 | $90.18M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $20.12M 10-Q · filed 2026-08-06 | $43.11M 10-Q · filed 2026-08-06 | $69.80M derived: sum of 3 quarters · filed 2026-08-06 | $93.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $23.00M 10-Q · filed 2026-05-07 | $49.68M derived: sum of 2 quarters · filed 2026-05-07 | $73.62M derived: sum of 3 quarters · filed 2026-05-07 | $97.54M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $26.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $50.62M derived: sum of 2 quarters · filed 2026-03-04 | $74.54M derived: sum of 3 quarters · filed 2026-03-04 | $100.89M 10-K · filed 2026-03-04 |
| 2024-09-30 | $23.94M 10-Q · filed 2025-11-04 | $47.85M derived: sum of 2 quarters · filed 2025-11-04 | $74.21M 10-Q · filed 2025-11-04 | $100.24M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $23.92M 10-Q · filed 2025-08-06 | $50.27M 10-Q · filed 2025-08-06 | $76.30M derived: sum of 3 quarters · filed 2025-08-06 | $102.09M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $26.35M 10-Q · filed 2025-05-08 | $52.38M derived: sum of 2 quarters · filed 2025-05-08 | $78.17M derived: sum of 3 quarters · filed 2025-05-08 | $104.56M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $26.03M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $51.82M derived: sum of 2 quarters · filed 2025-03-18 | $78.21M derived: sum of 3 quarters · filed 2025-03-18 | $103.58M 10-K · filed 2025-03-18 |
| 2023-09-30 | $25.79M 10-Q · filed 2024-11-12 | $52.18M derived: sum of 2 quarters · filed 2024-11-12 | $77.56M 10-Q · filed 2024-11-12 | $103.85M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $26.39M 10-Q · filed 2024-08-08 | $51.76M 10-Q · filed 2024-08-08 | $78.06M derived: sum of 3 quarters · filed 2024-08-08 | $99.88M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $25.37M 10-Q · filed 2024-05-09 | $51.67M derived: sum of 2 quarters · filed 2024-05-09 | $73.49M derived: sum of 3 quarters · filed 2024-05-09 | $93.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $26.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $48.11M derived: sum of 2 quarters · filed 2024-03-25 | $67.88M derived: sum of 3 quarters · filed 2024-03-25 | $85.72M 10-K · filed 2024-03-25 |
| 2022-09-30 | $21.82M 10-Q · filed 2023-11-09 | $41.58M derived: sum of 2 quarters · filed 2023-11-09 | $59.43M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $19.77M 10-Q · filed 2023-08-10 | $37.61M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $17.85M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $70.36M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |